Review



p53r280k  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc p53r280k
    P53r280k, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/pLenti6%2FV5-p53_wt+p53+(Plasmid+%2322945)/bio_rxiv__64898__2026__01__12__698947-197-21-29
    Average 93 stars, based on 43 article reviews
    p53r280k - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Generated:

    Article Title: PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugs
    Article Snippet: 2 days after transduction, cells were selected with 10□μg/mL of blasticidin S HCl (A1113903, Gibco) for 10 days. .. Lentiviral particles were generated with vectors encoding human p53 with a C-terminal V5 tag coding for WT p35, p53R175H, p53R249S, p53R273H, p53R280K (#22945, #22936, #22935, #22934 and #22933, respectively, Addgene, ( )) and the control vector pLenti CMV Blast DEST (706-1) (#17451, Addgene). ..

    Control:

    Article Title: PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugs
    Article Snippet: 2 days after transduction, cells were selected with 10□μg/mL of blasticidin S HCl (A1113903, Gibco) for 10 days. .. Lentiviral particles were generated with vectors encoding human p53 with a C-terminal V5 tag coding for WT p35, p53R175H, p53R249S, p53R273H, p53R280K (#22945, #22936, #22935, #22934 and #22933, respectively, Addgene, ( )) and the control vector pLenti CMV Blast DEST (706-1) (#17451, Addgene). ..

    Plasmid Preparation:

    Article Title: PROTAC-Driven Protective Therapy increases the therapeutic window of anticancer drugs
    Article Snippet: 2 days after transduction, cells were selected with 10□μg/mL of blasticidin S HCl (A1113903, Gibco) for 10 days. .. Lentiviral particles were generated with vectors encoding human p53 with a C-terminal V5 tag coding for WT p35, p53R175H, p53R249S, p53R273H, p53R280K (#22945, #22936, #22935, #22934 and #22933, respectively, Addgene, ( )) and the control vector pLenti CMV Blast DEST (706-1) (#17451, Addgene). ..



    Similar Products

    93
    Addgene inc p53r280k
    P53r280k, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/pLenti6%2FV5-p53_wt+p53+(Plasmid+%2322945)/bio_rxiv__64898__2026__01__12__698947-197-21-29
    Average 93 stars, based on 1 article reviews
    p53r280k - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    99
    ATCC bt474 p53r280k
    Fig. 4 Binding of endogenously processed p53125–134/A24 pMHCs on cells expressing wild-type and mutant p53. a Colon carcinoma cell line HT29 expressing HLA-A24 and mutant p53R273H, osteosarcoma cell line SaoS2 expressing HLA-A24 with a null mutation of the p53 gene, while hepatocellular carcinoma cell line HepG2-expressing HLA-A24 and wild-type p53 were stained with 10 µg mL−1 P1C1TM. Significant staining was observed only with HT29 cells and minimal staining or no staining was seen with HepG2 and SaoS2 cells, respectively. HLA-A24-negative breast cancer cell lines MDA-MB- 231, <t>BT474</t> and MCF7, and lung carcinoma cell line A549 were transduced with HLA-A24. Staining of the untransduced (b) and transduced (c) cells with P1C1TM showed significantly higher levels of p53125–134/A24 pMHCs on the surface of cells expressing both HLA-A24 and mutant p53 (MDA-MB-231 and BT474) compared to cells expressing wild-type p53 (A549 and MCF7). Insets show P1C1TM staining of the respective cell lines pulsed with 10 μM of p53125–134 peptides, indicating successful transduction. Data are representative of three independent experiments. d P1C1TM was used to stain HLA-A24+
    Bt474 P53r280k, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/BT-474/pm31772160-256-23-40
    Average 99 stars, based on 1 article reviews
    bt474 p53r280k - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    90
    Genechem p53r280k cdna plasmid
    a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of <t>REV1</t> and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). ** p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, ** p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. * p < 0.05, ** p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments
    P53r280k Cdna Plasmid, supplied by Genechem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/p53r280k+cdna+plasmid/pmc06739306-208-44-57
    Average 90 stars, based on 1 article reviews
    p53r280k cdna plasmid - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    NZYTech Inc expression plasmid petm20-p53r280k
    a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of <t>REV1</t> and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). ** p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, ** p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. * p < 0.05, ** p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments
    Expression Plasmid Petm20 P53r280k, supplied by NZYTech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/expression+plasmid+petm20+p53r280k/pmc05979565-142-1-15
    Average 90 stars, based on 1 article reviews
    expression plasmid petm20-p53r280k - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    99
    ATCC human tnbc cells mda mb 231 p53r280k
    a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of <t>REV1</t> and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). ** p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, ** p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. * p < 0.05, ** p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments
    Human Tnbc Cells Mda Mb 231 P53r280k, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/MDA-MB-231/pm26876786-42-0-25
    Average 99 stars, based on 1 article reviews
    human tnbc cells mda mb 231 p53r280k - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    ATCC human mutp53 breast cancer cells mda231 p53r280k
    a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of <t>REV1</t> and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). ** p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, ** p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. * p < 0.05, ** p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments
    Human Mutp53 Breast Cancer Cells Mda231 P53r280k, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/MDA-MB-231/10__1158_slash_1541___7786__mcr___14___0360-50-0-10
    Average 99 stars, based on 1 article reviews
    human mutp53 breast cancer cells mda231 p53r280k - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    85
    Addgene inc pcdna3 p53r280k
    a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of <t>REV1</t> and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). ** p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, ** p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. * p < 0.05, ** p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments
    Pcdna3 P53r280k, supplied by Addgene inc, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/p53r280k/pXJ40-HA-Merlin+I+S518D+(Plasmid+%2319701)/pm24658687-437-4-2
    Average 85 stars, based on 1 article reviews
    pcdna3 p53r280k - by Bioz Stars, 2026-11
    85/100 stars
      Buy from Supplier

    Image Search Results


    Fig. 4 Binding of endogenously processed p53125–134/A24 pMHCs on cells expressing wild-type and mutant p53. a Colon carcinoma cell line HT29 expressing HLA-A24 and mutant p53R273H, osteosarcoma cell line SaoS2 expressing HLA-A24 with a null mutation of the p53 gene, while hepatocellular carcinoma cell line HepG2-expressing HLA-A24 and wild-type p53 were stained with 10 µg mL−1 P1C1TM. Significant staining was observed only with HT29 cells and minimal staining or no staining was seen with HepG2 and SaoS2 cells, respectively. HLA-A24-negative breast cancer cell lines MDA-MB- 231, BT474 and MCF7, and lung carcinoma cell line A549 were transduced with HLA-A24. Staining of the untransduced (b) and transduced (c) cells with P1C1TM showed significantly higher levels of p53125–134/A24 pMHCs on the surface of cells expressing both HLA-A24 and mutant p53 (MDA-MB-231 and BT474) compared to cells expressing wild-type p53 (A549 and MCF7). Insets show P1C1TM staining of the respective cell lines pulsed with 10 μM of p53125–134 peptides, indicating successful transduction. Data are representative of three independent experiments. d P1C1TM was used to stain HLA-A24+

    Journal: Nature communications

    Article Title: Targeting mutant p53-expressing tumours with a T cell receptor-like antibody specific for a wild-type antigen.

    doi: 10.1038/s41467-019-13305-z

    Figure Lengend Snippet: Fig. 4 Binding of endogenously processed p53125–134/A24 pMHCs on cells expressing wild-type and mutant p53. a Colon carcinoma cell line HT29 expressing HLA-A24 and mutant p53R273H, osteosarcoma cell line SaoS2 expressing HLA-A24 with a null mutation of the p53 gene, while hepatocellular carcinoma cell line HepG2-expressing HLA-A24 and wild-type p53 were stained with 10 µg mL−1 P1C1TM. Significant staining was observed only with HT29 cells and minimal staining or no staining was seen with HepG2 and SaoS2 cells, respectively. HLA-A24-negative breast cancer cell lines MDA-MB- 231, BT474 and MCF7, and lung carcinoma cell line A549 were transduced with HLA-A24. Staining of the untransduced (b) and transduced (c) cells with P1C1TM showed significantly higher levels of p53125–134/A24 pMHCs on the surface of cells expressing both HLA-A24 and mutant p53 (MDA-MB-231 and BT474) compared to cells expressing wild-type p53 (A549 and MCF7). Insets show P1C1TM staining of the respective cell lines pulsed with 10 μM of p53125–134 peptides, indicating successful transduction. Data are representative of three independent experiments. d P1C1TM was used to stain HLA-A24+

    Article Snippet: MDA-MB-231 (expressing p53 with a mutation at Arg280 to a Lys, i.e. p53R280K) (cat. #HTB-26), A549 (wild-type p53 expressing, i.e. p53wt) (cat. #CCL-185), BT474 (p53R280K) (cat. #HTB-20), MCF7 (p53wt) (cat. #HTB-22) and HepG2 cells (p53wt) (cat. #HB-8065) were purchased from ATCC.

    Techniques: Binding Assay, Expressing, Mutagenesis, Staining, Transduction

    a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of REV1 and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). ** p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, ** p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. * p < 0.05, ** p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments

    Journal: Cell Death & Disease

    Article Title: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response

    doi: 10.1038/s41419-019-1871-z

    Figure Lengend Snippet: a qRT-PCR and b Western blot analyses showing the mRNA and protein expression of REV1 and FANCF in untreated MCF-7 and MDA-MB-231 cells (blank), as well as cells transfected with miR-30a, miR-30b, miR-30c, miR-30d, miR-30e mimic and negative control (NC, scrambled control oligonucleotides). ** p < 0.01 vs. NC group. c The REV1 and FANCF 3′UTR binding sites of miR-30c and the REV1 and FANCF 3′UTR mutation sites in the mutated luciferase plasmid. d Dual-luciferase activity in 293 T cells transfected with miR-30c mimic (20 nM), NC (20 nM) and a wild-type or mutated 3′UTR of REV1 or FANCF, ** p < 0.01 vs. NC group. NS indicates no significant difference. NC: negative control, scrambled control oligonucleotides. e Western blot analysis showing the protein expression of REV1, FANCF, and FANCD2 in MCF-7 and MDA-MB-231 cells transfected with miR-30c inhibitors (20 nM) or the NC inhibitor (20 nM) and untreated MCF-7 and MDA-MB-231 cells (Blank). The graph showing the statistical results is located on the right. * p < 0.05, ** p < 0.01 vs. Inh-NC group. Data represent the mean ± SD of three independent experiments

    Article Snippet: The BrCa cell lines MCF-7, ZR-75-1, T-47D, MDA-MB-231 (ATCC, USA) and MCF-10A (ATCC, USA) were cultured under standard conditions, as recommended by their manufacturers. pMKO.1 puro p53 shRNA (Plasmid #10671) and pCMV-Neo-Bam p53wt (Plasmid #16434) were obtained from Addgene ( http://www.addgene.org ). p53R280K cDNA, REV1 cDNA and FANCF cDNA plasmids without 3′ UTR region were obtained from GeneChem ( www.genechem.com.cn ).

    Techniques: Quantitative RT-PCR, Western Blot, Expressing, Transfection, Negative Control, Control, Binding Assay, Mutagenesis, Luciferase, Plasmid Preparation, Activity Assay

    a Real-time PCR analysis of miR-30c basal expression in wtp53 (MCF-10A, MCF-7, and ZR-75-1) and mutp53 (MDA-MB-231, and T-47D) BrCa cells. * p < 0.05, wtp53 vs. mutp53 BrCa. b wtp53 and mutp53 BrCa cells were treated with ADR (0.5 µM) for 48 h. The expression of miR-30c was evaluated by qRT-PCR. * p < 0.05,** p < 0.01 vs. control group. NS indicates no significant difference. c MDA-MB-231 and T47D cells were transiently transfected with the NC or miR-30c mimic and were treated with various ADR concentrations. The relative viability of the MDA-MB-231 and T47D cells was determined via CCK-8 assays ( n = 3). * p < 0.05 vs. NC group. d The relative viability of the MDA-MB-231and T47D cells was detected by CCK-8 assays 48 h after transfection with NC (20 nM), miR-30c mimic (20 nM), FANCF (4 µg), REV1 cDNA(4 µg) or FANCF and REV1 cDNA. FANCF and REV1 constructs are plasmids without 3′ UTR region. # p < 0.05 vs. miR-30c group, * p < 0.05 vs. NC group. e MCF-7 and MDA-MB-231 cells were injected subcutaneously into nude mice. A cholesterol-conjugated miR-30c agomir or negative control (NC) agomir was intratumorally injected 7 days after tumor formation, and agomir and ADR were intratumorally injected every two days ( n = 5). f Xenograft tumor growth was monitored. # p < 0.05, ## p < 0.01 vs. ADR group; * p < 0.05, ** p < 0.01 vs. NC(-) agomir group. g Tumor weight at sacrifice. * p < 0.05, *** p < 0.001 vs. NC(−) agomir group; # p < 0.05, ### p < 0.001 vs. ADR group. Data represent the mean ± SD ( n = 5, each group). h Photographs of the removed tumors at day 34 after the implantation. i Western blot analysis for FANCF and REV1 in the MCF-7 and MDA-MB-231 xenografts after treatment with the cholesterol-conjugated miR-30c agomir or the NC agomir. ** p < 0.01 vs. NC group

    Journal: Cell Death & Disease

    Article Title: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response

    doi: 10.1038/s41419-019-1871-z

    Figure Lengend Snippet: a Real-time PCR analysis of miR-30c basal expression in wtp53 (MCF-10A, MCF-7, and ZR-75-1) and mutp53 (MDA-MB-231, and T-47D) BrCa cells. * p < 0.05, wtp53 vs. mutp53 BrCa. b wtp53 and mutp53 BrCa cells were treated with ADR (0.5 µM) for 48 h. The expression of miR-30c was evaluated by qRT-PCR. * p < 0.05,** p < 0.01 vs. control group. NS indicates no significant difference. c MDA-MB-231 and T47D cells were transiently transfected with the NC or miR-30c mimic and were treated with various ADR concentrations. The relative viability of the MDA-MB-231 and T47D cells was determined via CCK-8 assays ( n = 3). * p < 0.05 vs. NC group. d The relative viability of the MDA-MB-231and T47D cells was detected by CCK-8 assays 48 h after transfection with NC (20 nM), miR-30c mimic (20 nM), FANCF (4 µg), REV1 cDNA(4 µg) or FANCF and REV1 cDNA. FANCF and REV1 constructs are plasmids without 3′ UTR region. # p < 0.05 vs. miR-30c group, * p < 0.05 vs. NC group. e MCF-7 and MDA-MB-231 cells were injected subcutaneously into nude mice. A cholesterol-conjugated miR-30c agomir or negative control (NC) agomir was intratumorally injected 7 days after tumor formation, and agomir and ADR were intratumorally injected every two days ( n = 5). f Xenograft tumor growth was monitored. # p < 0.05, ## p < 0.01 vs. ADR group; * p < 0.05, ** p < 0.01 vs. NC(-) agomir group. g Tumor weight at sacrifice. * p < 0.05, *** p < 0.001 vs. NC(−) agomir group; # p < 0.05, ### p < 0.001 vs. ADR group. Data represent the mean ± SD ( n = 5, each group). h Photographs of the removed tumors at day 34 after the implantation. i Western blot analysis for FANCF and REV1 in the MCF-7 and MDA-MB-231 xenografts after treatment with the cholesterol-conjugated miR-30c agomir or the NC agomir. ** p < 0.01 vs. NC group

    Article Snippet: The BrCa cell lines MCF-7, ZR-75-1, T-47D, MDA-MB-231 (ATCC, USA) and MCF-10A (ATCC, USA) were cultured under standard conditions, as recommended by their manufacturers. pMKO.1 puro p53 shRNA (Plasmid #10671) and pCMV-Neo-Bam p53wt (Plasmid #16434) were obtained from Addgene ( http://www.addgene.org ). p53R280K cDNA, REV1 cDNA and FANCF cDNA plasmids without 3′ UTR region were obtained from GeneChem ( www.genechem.com.cn ).

    Techniques: Real-time Polymerase Chain Reaction, Expressing, Quantitative RT-PCR, Control, Transfection, CCK-8 Assay, Construct, Injection, Negative Control, Western Blot

    a Schematic representation of NFYC (miR-30c host gene) and putative p53 binding sites in intron 5 of NFYC . b HEK-293T cells were treated with pcDNA3.1-p53 (wtp53), pcDNA3.1-p53R280K (mutp53), ADR (0.5 µM), pifithrin-α (10 µM), pifithrin-α + ADR or the miR-30c promoter constructs (in the pGL3 vector). Relative luciferase activity was assayed. ** p < 0.01 vs. PGL3 vector, ## p < 0.01 vs. pifithrin-α group. c ChIP assay showing endogenous p53 bound to the miR-30c promoter in the p53 binding site region in MCF-7 cells. d MCF-7 and MDA-MB-231 cells were treated with ADR (0.5 µM) for 12, 24, and 48 h. The expression of mature miR-30c and pri-miR-30c was evaluated by qRT-PCR. The protein expression of p-p53, p53, and p21 was examined by Western blotting. * p < 0.05, ** p < 0.01 vs. 0 h group. e MCF-7 and MDA-MB-231 cells were treated with control, p53shRNA, ADR, or p53shRNA + ADR for 48 h. qRT-PCR showed that the miR-30c expression changes. The protein expression of p53 was examined by Western blotting. f MCF-7 and MDA-MB-231 cells were transfected with NC inhibitor (20 nM) or miR-30c inhibitor (20 nM) and were then treated with ADR and p53cDNA. The expression of FANCF and REV1 was analyzed by Western blotting. MCF-7 cells: * p < 0.05, ** p < 0.01 vs. Blank group; # p < 0.05 vs. ADR group, ## p < 0.01, vs. p53cDNA group. MDA-MD-231 cells: * p < 0.05 vs. Blank group; # p < 0.05 vs. p53cDNA group. g FANCF and REV1 expression in MCF-7 and MDA-MB-231 cells transfected with p53 shRNA, miR-30c mimic (miR-30c) or the negative control (NC). The expression of FANCF and REV1 was analyzed by Western blotting. ** p < 0.01, *** p < 0.001 vs. Blank group; # p < 0.05 vs. Blank group. h qRT-PCR analysis of miR-30c expression in ADR-treated MCF-7 and MDA-MB-231 xenografts. Western blot analysis of p-p53, p53, FANCF, and REV1 expression in ADR-treated MCF-7 and MDA-MB-231 xenografts. ** p < 0.01, *** p < 0.001 vs. Blank group. NS indicates no significant difference. Data represent the mean ± SD ( n = 3, each group)

    Journal: Cell Death & Disease

    Article Title: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response

    doi: 10.1038/s41419-019-1871-z

    Figure Lengend Snippet: a Schematic representation of NFYC (miR-30c host gene) and putative p53 binding sites in intron 5 of NFYC . b HEK-293T cells were treated with pcDNA3.1-p53 (wtp53), pcDNA3.1-p53R280K (mutp53), ADR (0.5 µM), pifithrin-α (10 µM), pifithrin-α + ADR or the miR-30c promoter constructs (in the pGL3 vector). Relative luciferase activity was assayed. ** p < 0.01 vs. PGL3 vector, ## p < 0.01 vs. pifithrin-α group. c ChIP assay showing endogenous p53 bound to the miR-30c promoter in the p53 binding site region in MCF-7 cells. d MCF-7 and MDA-MB-231 cells were treated with ADR (0.5 µM) for 12, 24, and 48 h. The expression of mature miR-30c and pri-miR-30c was evaluated by qRT-PCR. The protein expression of p-p53, p53, and p21 was examined by Western blotting. * p < 0.05, ** p < 0.01 vs. 0 h group. e MCF-7 and MDA-MB-231 cells were treated with control, p53shRNA, ADR, or p53shRNA + ADR for 48 h. qRT-PCR showed that the miR-30c expression changes. The protein expression of p53 was examined by Western blotting. f MCF-7 and MDA-MB-231 cells were transfected with NC inhibitor (20 nM) or miR-30c inhibitor (20 nM) and were then treated with ADR and p53cDNA. The expression of FANCF and REV1 was analyzed by Western blotting. MCF-7 cells: * p < 0.05, ** p < 0.01 vs. Blank group; # p < 0.05 vs. ADR group, ## p < 0.01, vs. p53cDNA group. MDA-MD-231 cells: * p < 0.05 vs. Blank group; # p < 0.05 vs. p53cDNA group. g FANCF and REV1 expression in MCF-7 and MDA-MB-231 cells transfected with p53 shRNA, miR-30c mimic (miR-30c) or the negative control (NC). The expression of FANCF and REV1 was analyzed by Western blotting. ** p < 0.01, *** p < 0.001 vs. Blank group; # p < 0.05 vs. Blank group. h qRT-PCR analysis of miR-30c expression in ADR-treated MCF-7 and MDA-MB-231 xenografts. Western blot analysis of p-p53, p53, FANCF, and REV1 expression in ADR-treated MCF-7 and MDA-MB-231 xenografts. ** p < 0.01, *** p < 0.001 vs. Blank group. NS indicates no significant difference. Data represent the mean ± SD ( n = 3, each group)

    Article Snippet: The BrCa cell lines MCF-7, ZR-75-1, T-47D, MDA-MB-231 (ATCC, USA) and MCF-10A (ATCC, USA) were cultured under standard conditions, as recommended by their manufacturers. pMKO.1 puro p53 shRNA (Plasmid #10671) and pCMV-Neo-Bam p53wt (Plasmid #16434) were obtained from Addgene ( http://www.addgene.org ). p53R280K cDNA, REV1 cDNA and FANCF cDNA plasmids without 3′ UTR region were obtained from GeneChem ( www.genechem.com.cn ).

    Techniques: Binding Assay, Construct, Plasmid Preparation, Luciferase, Activity Assay, Expressing, Quantitative RT-PCR, Western Blot, Control, Transfection, shRNA, Negative Control

    a miR-30c expression in normal breast tissues ( n = 113) and BrCa tissues ( n = 1109) in The Cancer Genome Atlas (TCGA) dataset. The p value was calculated via a nonparametric Mann-Whitney test. b Kaplan–Meier overall survival curves according to miR-30c expression in METABRIC BrCa patient cohorts. c A whisker plot showing miR-30c expression in patients with mutp53 tumors ( n = 285) and wtp53 tumors (n = 775) using TCGA database. d Representative images of miR-30c in situ hybridization and FANCF and REV1 IHC for 118 cases of BrCa expressing wtp53 and mutp53. Magnification, ×200. Small frames indicate the magnified regions. e Quantitative data for miR-30c, FANCF and REV1 protein staining in d . Statistical significance was determined by Wilcoxon rank-sum tests. f Correlation analysis of miR-30c and REV1 or FANCF protein expression in BrCa patients

    Journal: Cell Death & Disease

    Article Title: Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response

    doi: 10.1038/s41419-019-1871-z

    Figure Lengend Snippet: a miR-30c expression in normal breast tissues ( n = 113) and BrCa tissues ( n = 1109) in The Cancer Genome Atlas (TCGA) dataset. The p value was calculated via a nonparametric Mann-Whitney test. b Kaplan–Meier overall survival curves according to miR-30c expression in METABRIC BrCa patient cohorts. c A whisker plot showing miR-30c expression in patients with mutp53 tumors ( n = 285) and wtp53 tumors (n = 775) using TCGA database. d Representative images of miR-30c in situ hybridization and FANCF and REV1 IHC for 118 cases of BrCa expressing wtp53 and mutp53. Magnification, ×200. Small frames indicate the magnified regions. e Quantitative data for miR-30c, FANCF and REV1 protein staining in d . Statistical significance was determined by Wilcoxon rank-sum tests. f Correlation analysis of miR-30c and REV1 or FANCF protein expression in BrCa patients

    Article Snippet: The BrCa cell lines MCF-7, ZR-75-1, T-47D, MDA-MB-231 (ATCC, USA) and MCF-10A (ATCC, USA) were cultured under standard conditions, as recommended by their manufacturers. pMKO.1 puro p53 shRNA (Plasmid #10671) and pCMV-Neo-Bam p53wt (Plasmid #16434) were obtained from Addgene ( http://www.addgene.org ). p53R280K cDNA, REV1 cDNA and FANCF cDNA plasmids without 3′ UTR region were obtained from GeneChem ( www.genechem.com.cn ).

    Techniques: Expressing, MANN-WHITNEY, Whisker Assay, In Situ Hybridization, Staining